|1.||Andersson, Borje S: 23 articles (11/2015 - 01/2002)|
|2.||Champlin, Richard E: 20 articles (06/2015 - 01/2002)|
|3.||Nagler, Arnon: 10 articles (11/2015 - 01/2003)|
|4.||Mohty, Mohamad: 10 articles (09/2015 - 10/2003)|
|5.||de Lima, Marcos: 10 articles (12/2013 - 01/2002)|
|6.||Valdez, Benigno C: 9 articles (11/2015 - 11/2008)|
|7.||Blaise, Didier: 9 articles (09/2015 - 10/2003)|
|8.||Sanz, Miguel A: 9 articles (05/2015 - 06/2003)|
|9.||Anasetti, Claudio: 8 articles (06/2015 - 01/2002)|
|10.||McCune, Jeannine S: 8 articles (07/2014 - 05/2006)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/01/2013 - "A wide range of busulfan exposures were targeted for children with the same disease (eg, 39 target busulfan exposures for the 264 children diagnosed with acute myeloid leukemia). "
02/01/2005 - "Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD. "
09/01/2000 - "Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia."
01/01/1994 - "Moreover, patients with acute myelogenous leukemia or those transplanted after busulfan or total-body irradiation conditioning regimens had a slower engraftment (p < 0.08). "
01/01/1987 - "Allogeneic BMT in acute nonlymphoblastic leukemia (ANLL) following busulfan (Bu) resulted in DFS for CR1, CR2 + CR3 + early relapse of 21/47 (45%) and 13/41 (32%), respectively. "
|2.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/01/1989 - "[Appearance of chromosomally normal hemopoiesis during busulfan-induced remission in a case of Ph1 positive chronic myelogenous leukemia]."
01/01/1985 - "Survival in 73 patients with Ph1-positive chronic myelocytic leukemia was correlated with remission duration and leukocyte doubling time after initial treatment with busulfan and also, with clinical and laboratory features recorded at the time of diagnosis. "
01/01/1966 - "Prolonged remission in chronic myeloid leukemia after one course of busulfan."
07/01/1965 - "Prolonged remission in chronic myeloid leukemia after a single course of myleran."
05/01/1989 - "[A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan]."
11/01/1996 - "Children with inherited disorders eliminated busulphan significantly faster after the first and the last dose with half-lives (t1/2) of 1.93 and 1.71 h, respectively compared to children with leukemia (3.16 and 2.70 h, respectively). "
01/01/2015 - "In this study, we investigated the cytotoxic effects and underlying mechanisms in leukemia stem-like KG1a cells exposed to busulfan (BUS) and CUR, either alone or in combination. "
11/01/2006 - "Busulfan (BU) is a unique alkylating agent that primarily targets slowly proliferating or nonproliferating cells in the body, leading to various normal tissue damage while killing leukemia cells. "
09/01/2003 - "Serum samples of 15 pediatric patients with leukemia were analyzed for busulfan and cytokine levels. "
08/01/2002 - "Two years elapsed between the diagnosis of leukemia and the start of busulfan therapy. "
|4.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
06/01/1994 - "Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes."
01/01/2002 - "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality."
04/15/1993 - "Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS). "
04/15/1993 - "Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes."
11/01/2014 - "Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
09/01/2013 - "This study confirms that myeloablative sUCBT using busulfan-based conditioning is a valuable strategy for patients with hematological malignancies. "
01/01/2016 - "Standard myeloablative conditioning regimens for children with hematological malignancies undergoing allogeneic HSCT are based mainly on total body irradiation or busulfan. "
08/01/2005 - "Fifteen heavily pretreated high-risk patients (age 25-66, median 42 years) with hematologic malignancies were conditioned with busulfan alone, 4mg/kg/day for 2, 3, or 4 consecutive days. "
01/01/1996 - "Toxicity profiles of 25 pediatric patients with hematologic malignancies undergoing intensified conditioning did not differ significantly between the two groups, except for a higher incidence of veno-occlusive disease in busulfan-treated patients (3 of 13 patients) compared with the TBI group (0 of 12 patients). "
04/01/1993 - "The combination of busulfan and CY ('BU-CY') has been widely employed as a conditioning regimen for patients undergoing BMT for hematologic malignancies. "
|5.||Etoposide (VP 16)
|7.||Antilymphocyte Serum (Anti-Thymocyte Globulin)
|8.||Interferon-alpha (Interferon Alfa)
|1.||Hematopoietic Stem Cell Transplantation
|2.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)
|4.||Stem Cell Transplantation
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)